United Kingdom Archives

alnylam silence therapeutics lawsuit settlement

News and Trends 11 Dec 2018

UK Biotech Settles Lawsuit on the First RNAi Drug

Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal dispute between them resulting in Silence receiving some royalties on Onpattro, the first RNA interference drug. The lawsuit started last year, when Silence went to the UK courts claiming that Alnylam was infringing on its intellectual property. As part of […]

December 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

genomics machine learning personalized medicine

More News! 10 Dec 2018

British Company Raises €37M to Personalize Therapies with Machine Learning

Genomics, a company based in Oxford, has increased the amount raised in a Series B round that will fund further development of its genomics technology for personalized medicine. The company adds a further €9M (£8M) to the round with the participation of Foresite Capital and F-Prime Capital, two renowned US life sciences investors. The previous […]

December 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Dec 2018

Orchard’s Gene Therapy for Rare Immune Disease Works for Over a Year

A single dose of a gene therapy developed by Orchard Therapeutics can restore immune function for at least a year in patients with X-linked chronic granulomatous disease (X-CGD). The gene therapy was trialed in patients between the ages of 2 and 27 with the rare disease, which is caused by a rare genetic mutation that […]

December 7, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Dec 2018

Update: Liver Gene Therapy 8 Times Stronger Than Usual

Update (06/12/2018): uniQure has incorporated Synpromics’ strong liver promoter into a preclinical gene therapy candidate for treating hemophilia A. Published on 08/10/2018 Synpromics and uniQure have unveiled new technology for precise genetic control that could make gene therapy safer and more precise. The team has developed a gene therapy system that is highly selective for […]

December 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Nov 2018

Update: UK Biotech Scores £5M Series A to Boost Next-Generation Cancer Antibodies

Update (30/11/2018): IGEM Therapeutics has increased the total raised in Series A to £5M (€5.6M) with the participation of two new investors, Alsa Holdings and UCL Technology Fund. The funding will go towards the development of a new generation of antibody drugs for cancer. Published on 20/06/2017 IGEM Therapeutics has raised £2M (€2.3M) in Series A […]

November 30, 2018 - 2 minutesmins - By Melanie De Almeida

momentum bioscience blood infection sepsis UK cardiff

Startup Scout 30 Nov 2018

This Biotech Speeds Up Blood Infection Diagnosis

In the city of Cardiff, UK, Momentum Bioscience aims to trim down the unnecessary use of antimicrobial drugs in hospitals. To do this, it is developing molecular diagnostics that, within hours, tell doctors when or when not to use antibiotics in patients with a suspected blood infection. Mission: When diagnosing blood infections, physicians often need […]

November 30, 2018 - 3 minutesmins - By Jonathan Smith

cambridge nature placenta organoid stemcell fetus

More News! 29 Nov 2018

Long-Lasting Placenta Organoids Could Improve Pregnancy Research

Researchers have made 3D placenta organoids from human cells that can last for over a year, improving over the current models to study disease in pregnancy and develop drugs. Researchers at the University of Cambridge grew the organoids from stem cells extracted from donated placenta tissue at 6-9 weeks of pregnancy. The organoids replicated the […]

November 29, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 26 Nov 2018

Smart Asthma Inhaler Fails Phase III

It is bad news for asthma sufferers, as a UK biotech has abandoned the development of its smart inhaler after finding that it was no better than placebo in a Phase III trial. Over 52 weeks of treatment, the company Vectura tested whether the inhaler reduced the worsening of asthma symptoms, such as wheezing and […]

November 26, 2018 - 2 minutesmins - By Jonathan Smith

genentech immunocore immunotherapy pipette

News and Trends 20 Nov 2018

Genentech and Immunocore Expand Partnership to Develop Cancer Immunotherapy

Immunocore and the US biotech giant Genentech are building on their existing partnership to boost the clinical development of Immunocore’s immunotherapy for treating solid tumors. In the agreement, Genentech, a member of the Roche group, will pay UK-based Immunocore €87.3M ($100M) in an upfront payment and further undisclosed milestone payments as the immunotherapy progresses towards […]

November 20, 2018 - 2 minutesmins - By Jonathan Smith

More News! 12 Nov 2018

This UK Biotech Wants to Make Antibodies Easy to Swallow

Say goodbye to painful antibody injections. The UK biotech Intract Pharma has received a €1.6M grant to advance oral immunotherapy based on approved antibodies, causing less discomfort for patients. The grant, awarded by public agency Innovate UK, will help Intract develop oral versions of existing antibody therapies. This could make the treatments easier for patients […]

November 12, 2018 - 2 minutesmins - By Jonathan Smith

huntingtons epigenetics oxford biodynamics

News and Trends 8 Nov 2018

Epigenetics Test Can Distinguish Between Huntington’s Disease Stages

A study run by Oxford BioDynamics suggests that we could predict Huntington’s more easily by analyzing epigenetic changes in the patient’s DNA. Epigenetics describes the way that the expression of our genes is regulated, often influenced by environmental exposure, without changing the genetic code. Ways of modifying gene expression include attaching chemical groups to DNA […]

November 8, 2018 - 2 minutesmins - By Jonathan Smith

Orchard therapeutics gene therapy header

News and Trends 1 Nov 2018

Gene Therapy Company’s IPO Shoots it to Billion-Euro Biotech List

Orchard Therapeutics, a British company developing gene therapy for rare genetic diseases, has launched its Nasdaq IPO and is now reportedly worth $1.25B (€1B). This IPO propels Orchard to the handful of European biotechs worth €1B or more. The new money might help with the marketing and manufacture of Strimvelis, an EMA-approved gene therapy for […]

November 1, 2018 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

UK Biotech Settles Lawsuit on the First RNAi Drug

British Company Raises €37M to Personalize Therapies with Machine Learning

Orchard’s Gene Therapy for Rare Immune Disease Works for Over a Year

Update: Liver Gene Therapy 8 Times Stronger Than Usual

Update: UK Biotech Scores £5M Series A to Boost Next-Generation Cancer Antibodies

This Biotech Speeds Up Blood Infection Diagnosis

Long-Lasting Placenta Organoids Could Improve Pregnancy Research

Smart Asthma Inhaler Fails Phase III

Genentech and Immunocore Expand Partnership to Develop Cancer Immunotherapy

This UK Biotech Wants to Make Antibodies Easy to Swallow

Epigenetics Test Can Distinguish Between Huntington’s Disease Stages

Gene Therapy Company’s IPO Shoots it to Billion-Euro Biotech List

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!